MAPT and Alzheimer disease: Overall, these findings reinforce that, despite similar clinical presentations, Aβ+/tau- and Aβ+/tau + AD patients display distinct CSF proteomic profiles, both from each other and from non-AD controls, suggesting that they may represent biologically distinct subtypes of Alzheimer’s disease.